APDN · Applied Dna Sciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $197.3K | $250.0K | $299.3K | $612.5K | $512.5K | - | $552.3K | $634.0K | $660.1K | $1.65M |
| Gross Profit | $826.8K | $315.4K | $5.1K | $370.8K | $684.1K | - | $245.2K | $295.7K | $231.1K | $1.27M |
| R&D | $372.1K | $458.6K | $768.6K | $849.4K | $1.02M | - | $913.0K | $913.2K | $935.8K | $836.1K |
| SG&A | $2.59M | $13.35M | $2.93M | $2.98M | $2.63M | - | $2.68M | $3.00M | $3.08M | $3.29M |
| Total Operating Expenses | $7.58M | $19.02M | $3.70M | $3.83M | $3.65M | - | $3.59M | $3.91M | $4.02M | $4.13M |
| D&A | - | $48.8K | - | - | $58.6K | - | - | - | $299.0K | - |
| Operating Income | ($6.75M) | ($18.71M) | ($3.69M) | ($3.46M) | ($2.96M) | - | ($3.35M) | ($3.62M) | ($3.79M) | ($2.86M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | $0 |
| Net Income | ($6.67M) | ($18.59M) | ($3.95M) | ($3.30M) | ($2.64M) | - | $1.88M | ($4.47M) | ($1.11M) | ($3.10M) |
| EPS - Basic | ($0.68) | ($2.08) | ($34.00) | ($15.35) | ($0.56) | - | $0.47 | ($5.31) | ($0.09) | ($0.24) |
| EPS - Diluted | ($0.68) | ($2.08) | ($34.00) | ($15.35) | ($0.56) | - | $0.47 | ($5.31) | ($0.09) | ($0.24) |
Balance Sheet
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $949.1K | $2.45M | $1.67M | $6.82M | $9.29M | $10.10M | $6.43M | $3.15M | $3.36M | $7.15M |
| Accounts Receivable | $303.3K | $546.7K | $237.4K | $689.9K | $911.5K | - | $362.0K | $408.9K | $450.8K | $255.5K |
| Inventory | $115.4K | $90.0K | $84.1K | $348.9K | $468.6K | - | $438.6K | $335.9K | $377.3K | $330.0K |
| Accounts Payable | $839.6K | $1.25M | $844.8K | $885.0K | $1.23M | - | $1.17M | $1.13M | $1.02M | $1.07M |
| Current Assets | $2.68M | $5.11M | $2.24M | $8.43M | $11.28M | - | $8.05M | $4.36M | $4.59M | $8.13M |
| Total Assets | $13.63M | $20.70M | $4.44M | $13.04M | $15.97M | - | $12.79M | $9.18M | $9.91M | $13.65M |
| Current Liabilities | $1.47M | $2.21M | $2.46M | $1.89M | $2.39M | - | $2.40M | $2.62M | $2.59M | $2.85M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.50M | $2.24M | $2.50M | $2.81M | $3.42M | - | $3.82M | $9.35M | $5.78M | $8.78M |
| Stockholders' Equity | $12.51M | $18.84M | $2.30M | $10.46M | $12.75M | - | $9.14M | ($48.1K) | $4.23M | $4.95M |
| Retained Earnings | ($404.45M) | ($397.79M) | ($379.16M) | ($354.44M) | ($327.22M) | - | ($309.67M) | ($308.26M) | ($303.63M) | ($302.45M) |
Cash Flow
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($5.55M) | - | - | ($3.33M) | - | - | - | ($3.76M) | - |
| Investing Cash Flow | - | ($2.99M) | - | - | ($116.9K) | - | - | - | - | - |
| Financing Cash Flow | - | $9.32M | - | - | $6.31M | - | - | - | ($35.1K) | - |
| CapEx | - | - | - | - | $116.9K | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | ($3.44M) | - | - | - | - | - |
Ratios
| Metric | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 1.30 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -48.9% | -89.8% | -88.9% | -25.3% | -16.5% | - | 14.7% | -48.7% | -11.1% | -22.7% |
| Return on equity | -53.3% | -98.7% | -171.2% | -31.6% | -20.7% | - | 20.6% | 9284.9% | -26.1% | -62.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.82 | 2.32 | 0.91 | 4.45 | 4.72 | - | 3.36 | 1.66 | 1.77 | 2.86 |
| Quick ratio | 1.74 | 2.28 | 0.87 | 4.27 | 4.53 | - | 3.17 | 1.54 | 1.63 | 2.74 |
| Cash ratio | 0.64 | 1.11 | 0.68 | 3.60 | 3.89 | - | 2.68 | 1.20 | 1.30 | 2.51 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.09 | 1.10 | 1.93 | 1.25 | 1.25 | - | 1.40 | -190.57 | 2.34 | 2.76 |
| Liabilities / Assets | 0.11 | 0.11 | 0.56 | 0.22 | 0.21 | - | 0.30 | 1.02 | 0.58 | 0.64 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 1.71 | 2.78 | 3.56 | 1.76 | 1.09 | - | 1.26 | 1.89 | 1.75 | 4.99 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 213d | 131d | 103d | 208d | 334d | - | 290d | 193d | 209d | 73d |
| Days payable outstanding | 1553d | 1827d | 1030d | 527d | 879d | - | 770d | 649d | 562d | 237d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 122.9% | -53.9% | -97.9% | 25.4% | 196.0% | - | -80.7% | -83.6% | -90.3% | 22.1% |
| Operating income growth (YoY) | -95.0% | -531.2% | -10.4% | 4.3% | 21.8% | - | -17.1% | -33.8% | -210.8% | -0.8% |
| Net income growth (YoY) | -101.7% | -604.5% | - | 26.1% | -138.8% | - | - | - | 76.6% | -175.7% |
| EPS growth (YoY) | 95.6% | -271.4% | - | -189.1% | -522.2% | - | - | - | 70.0% | -84.6% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 19.6% | 47.7% | -74.8% | - | 201.3% | - | 84.7% | - | -53.8% | -61.7% |
Peer comparison
Same SIC group: Services-Testing Laboratories
Comparing APPLIED DNA SCIENCES INC against the 4 most active filers in the same SIC group.